Neoadjuvant Imatinib for an Uncommon Breast Malignancy Neoadjuvant Imatinib for an Uncommon Breast Malignancy
This case highlights the differentiation of dermatofibrosarcoma protuberans from metaplastic breast carcinoma and other spindle cell lesions, as well as the use of imatinib as neoadjuvant treatment.Journal of Medical Case Reports (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 18, 2020 Category: Surgery Tags: Family Medicine/Primary Care Journal Article Source Type: news

China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Media News - February 14, 2020 Category: Pharmaceuticals Source Type: news

China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Investor Update - February 14, 2020 Category: Pharmaceuticals Source Type: news

Roche to present new data on Tecentriq in combination with Avastin that shows improvement in overall survival for Chinese patients with the most common form of liver cancer
Basel, 7 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that additional data will be presented from a cohort of Chinese patients in the Phase III IMbrave150 study that evaluated Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. Data from 194 Chinese patients who took part in the IMbrave150 study were consistent with the global results, that showed a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free...
Source: Roche Investor Update - February 7, 2020 Category: Pharmaceuticals Source Type: news

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
      ·Application is being reviewed under FDA ’s Real-Time Oncology Review pilot programmeBasel, 27 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectab le hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, wh...
Source: Roche Investor Update - January 27, 2020 Category: Pharmaceuticals Source Type: news

RT for DCIS Ups Mortality Risk in Invasive Second Breast Cancer
FRIDAY, Dec. 20, 2019 -- For women with primary ductal carcinoma in situ (DCIS), use of radiotherapy (RT) is associated with increased rates of breast cancer-specific mortality for those women who subsequently develop an invasive second breast... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 20, 2019 Category: Pharmaceuticals Source Type: news

Patients with Invasive Secondary Breast Cancer May Have Higher Mortality
Patients who previously received radiotherapy for ductal carcinoma in situ may have higher mortality after developing an invasive second breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 3, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

New Study Suggests Women With Dense Breast Tissue May Benefit From Regular MRIs
While there has been some controversy over when women should start getting mammograms, all experts agree that screening is an important first step in detecting breast cancers and treating them early. But for some women, that’s not enough. For the approximately 40% of women with dense breast tissue, and especially the 10% with extremely dense tissue, cancer cells are harder to detect, since the denser tissue can mask small growths. In addition, dense breast tissue itself is also a risk factor for developing cancer. There’s been debate among experts over whether these women should have additional screening, on to...
Source: TIME: Health - November 27, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Breast Cancer embargoed study Research Source Type: news

Mesothelioma Death from 9/11 Signals Start of Things to Come
Malignant mesothelioma has become the latest deadly cancer linked directly to the rescue, recovery and cleanup efforts following the 9/11 terrorist attack on New York City in 2001. The long-running threat has come to fruition. Eighteen years after Manhattan was engulfed in the asbestos-laced, toxic cloud of dust — caused primarily by the World Trade Center destruction — the first death from pleural mesothelioma attributed to 9/11 has been recorded. Nick Ursta, 52, from the southwestern part of Pennsylvania, died after a year-long battle with the rare cancer. Ursta, a construction worker and fireman by trade, w...
Source: Asbestos and Mesothelioma News - November 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Palbociclib With Endocrine Therapy for HR+ Breast Carcinoma Palbociclib With Endocrine Therapy for HR+ Breast Carcinoma
In a new study, patients with HR+/HER2- early stage breast cancer completed 2 years of adjuvant palbociclib with a similar toxicity profile as that observed in the metastatic setting.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

No Benefit Seen for SLNB in BCS for DCIS in Older Women
THURSDAY, Oct. 31, 2019 -- For older patients with ductal carcinoma in situ (DCIS) who undergo breast-conserving surgery (BCS), sentinel lymph node biopsy (SLNB) is not associated with improvements in long-term outcomes, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 31, 2019 Category: Pharmaceuticals Source Type: news

Don't Delay Very Early-Stage Breast Cancer Surgery
Longer delays in surgery for ductal carcinoma in situ (DCIS) breast cancer lead to a higher risk of invasive ductal carcinoma and a slightly lower survival rate, researchers found. (Source: WebMD Health)
Source: WebMD Health - October 25, 2019 Category: Consumer Health News Source Type: news

Delay of Surgery for DCIS Ups Risk for Invasive Breast Cancer
FRIDAY, Oct. 25, 2019 -- For each month of delay between diagnosis and surgery for ductal carcinoma in situ (DCIS), there is slightly worse survival and an increase in risk for invasive disease, according to a study published online Sept. 27 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 25, 2019 Category: Pharmaceuticals Source Type: news

Sentinel lymph node biopsy unnecessary for DCIS
Performing sentinel lymph node biopsy in older women with ductal carcinoma...Read more on AuntMinnie.comRelated Reading: Chatbots boost women's understanding of breast biopsy Leica Biosystems unveils breast tissue biopsy container Biopsy rate is low after breast cancer 3D-printed breast biopsy device boosts accuracy Women overestimate breast cancer risk, prefer biopsy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 25, 2019 Category: Radiology Source Type: news

Don't Delay Surgery for Very Early-Stage Breast Cancer, Study Suggests
THURSDAY, Oct. 24, 2019 -- Delaying surgery for a noninvasive breast cancer can have dire consequences, a new study shows. Longer delays in surgery for ductal carcinoma in situ (DCIS) breast cancer lead to a higher risk of invasive ductal carcinoma... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 24, 2019 Category: General Medicine Source Type: news

Nodular Hiradenoma, a Rare Mimic of Breast Carcinoma Nodular Hiradenoma, a Rare Mimic of Breast Carcinoma
This case report summarizes the clinical, pathological, and immunohistochemical characteristics of a breast hidradenoma, an uncommon skin adnexal tumor arising from the eccrine or apocrine glands.Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 14, 2019 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Mother, 47, diagnosed with skin cancer INSIDE her breast in 'rare phenomenon'
Michelle Miller, from Florida, was diagnosed with squamous cell carcinoma on the inside of her breast in May, and had both her breasts removed before giving birth to her daughter, Macy, in July. (Source: the Mail online | Health)
Source: the Mail online | Health - August 28, 2019 Category: Consumer Health News Source Type: news

Reverse signaling by semaphorin 4C elicits SMAD1/5- and ID1/3-dependent invasive reprogramming in cancer cells
Semaphorins are a family of molecular signals that guide cell migration and are implicated in the regulation of cancer cells. In particular, transmembrane semaphorins are postulated to act as both ligands ("forward" mode) and signaling receptors ("reverse" mode); however, reverse semaphorin signaling in cancer is relatively less understood. Here, we identified a previously unknown function of transmembrane semaphorin 4C (Sema4C), acting in reverse mode, to elicit nonconventional TGF-β/BMP receptor activation and selective SMAD1/5 phosphorylation. Sema4C coimmunoprecipitated with TGFBRII and BMPR1, ...
Source: Signal Transduction Knowledge Environment - August 20, 2019 Category: Science Authors: Gurrapu, S., Franzolin, G., Fard, D., Accardo, M., Medico, E., Sarotto, I., Sapino, A., Isella, C., Tamagnone, L. Tags: STKE Research Articles Source Type: news

AI Program May Aid in Pathologic Evaluation of Breast Biopsies
FRIDAY, Aug. 16, 2019 -- An artificial intelligence program outperforms pathologists for differentiating ductal carcinoma in situ (DCIS) from atypia, according to a study published online Aug. 9 in JAMA Network Open. Ezgi Mercan, Ph.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 16, 2019 Category: Pharmaceuticals Source Type: news

Artificial intelligence could yield more accurate breast cancer diagnoses
UCLA researchers have developed an artificial intelligence system that could help pathologists read biopsies more accurately and to better detect and diagnose breast cancer.The new system,described in a study published today in JAMA Network Open, helps interpret medical images used to diagnose breast cancer that can be difficult for the human eye to classify, and it does so nearly as accurately or better as experienced pathologists.“It is critical to get a correct diagnosis from the beginning so that we can guide patients to the most effective treatments,” said Dr. Joann Elmore, the study’s senior author ...
Source: UCLA Newsroom: Health Sciences - August 9, 2019 Category: Universities & Medical Training Source Type: news

Medical News Today: What to know about mucinous carcinoma
Mucinous carcinoma is a rare type of cancer that usually affects the breast. In this article, we look at its symptoms, causes, treatments, and the outlook. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 15, 2019 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Medical News Today: What to know about tubular carcinoma
Tubular carcinoma is a type of invasive breast cancer. In this article, learn more about the symptoms, causes, and treatment of tubular carcinoma and the outlook for people with this cancer. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 4, 2019 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Medical News Today: What to know about medullary breast carcinoma
Medullary breast carcinoma is a rare type of invasive breast cancer. In this article, we look at the symptoms, causes, and treatment of medullary breast carcinoma and the outlook for people with this cancer. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 4, 2019 Category: Consumer Health News Tags: Breast Cancer Source Type: news

FBS-Put it to Work
Priced RightWe provide, to our customers, the sameFetal Bovine Serum (FBS) we use in ourdefined media. This FBS enriched media is used in culturing all our human 2 and 3-D based Assays. Our FBS is of the highest quality and priced right at $379/500 ml.Here're some recent publications referencing its use.Gabriela Fernandes, Stephen T Vanyo, Shahad Bakheet Alsharif, Sebastiano Andreana, Michelle B Visser, Rosemary Dziak, Ph.D.Strontium Effects on Human Gingival Fibroblasts. https://doi.org/10.1563/aaid-joi-D-18-00253Douglas Dickinson, Shannon Xayaraj, Sarah Dickinson, Xueling Shao, and Stephen Hsu.  Effect of ...
Source: Neuromics - June 27, 2019 Category: Neuroscience Tags: 3-D Cell based Assays Cell Cultures FBS Fetal Bovine Serum Source Type: news

Contrast ultrasound can tell DCIS from fibroadenomas
Contrast-enhanced ultrasound can distinguish ductal carcinoma in situ (DCIS)...Read more on AuntMinnie.comRelated Reading: Ultrasound options abound for diagnosing liver disease ICUS applauds payment changes for CEUS Contrast ultrasound helps characterize breast lesions Drop ultrasound contrast agent warning, society says Contrast US tops CT, MRI for classifying kidney tumors (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 19, 2019 Category: Radiology Source Type: news

Dr. Meyers on Low-Dose Tamoxifen vs Placebo After Surgery for DCIS Breast Cancer
Cancer Network spoke with Marleen Meyers, MD, about evidence on  low-dose tamoxifen vs placebo in women who had surgery for their ductal carcinoma in situ. (Source: CancerNetwork)
Source: CancerNetwork - June 17, 2019 Category: Cancer & Oncology Authors: Marleen Meyers, MD Source Type: news

Mesothelioma Clinical Trial Exploring Family Predisposition
The National Cancer Institute has opened a clinical trial using mesothelioma patients and their family members to explore predisposition to the cancer and potential solutions to negating it. The trial is a follow up to an earlier study of a genetic mutation that creates susceptibility to various cancers but a longer-than-normal survival with platinum-based chemotherapy treatment. “This is an important, long-term study that could have implications not only for a patient, but for family members, too,” Dr. Raffit Hassan, NCI senior investigator told The Mesothelioma Center at Asbestos.com. “Progress can be m...
Source: Asbestos and Mesothelioma News - May 20, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: A large study from a single institution
(Cancer Research UK) Upcoming publication from the British Journal of Cancer, investigating HER2 expression as a predictor of recurrence and development in patients with DCIS. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 7, 2019 Category: Cancer & Oncology Source Type: news

Six Factors Tied to DCIS Returning as Breast Cancer Six Factors Tied to DCIS Returning as Breast Cancer
A group of six factors are associated with ductal carcinoma in situ returning as invasive breast cancer after treatment.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 25, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Six factors may predict invasive breast cancer recurrence after DCIS diagnosis
(American Association for Cancer Research) Six factors were associated with invasive recurrence of breast cancer after a diagnosis of ductal carcinoma in situ (DCIS), according to data from a meta-analysis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 25, 2019 Category: Cancer & Oncology Source Type: news

Smart Biopsy Device Could Diagnose Breast Cancer Using Miniature Radiofrequency Sensors
Normally, when a physician notices a suspicious mass or lesion on a mammogram, he or she will request an ultrasound to explore it further. Based on those results, a biopsy may be performed to determine whether the mass is cancerous. “Unfortunately, right now, in some cases, physicians either overdiagnose or underdiagnose based on that biopsy, because with ultrasound they can only see so much,” said Lori Chmura, CEO of Dune Medical Devices. “The doctor is essentially going in blindly, trying to see what looks like the most suspicious area, and they’re t...
Source: MDDI - March 12, 2019 Category: Medical Devices Authors: Susan Shepard Tags: Business Source Type: news

Super-enhancers: novel target for pancreatic ductal adenocarcinoma
(Rapamycin Press) Among many pathways of cancer progression that PDAC relies on, anomalous activation of the sonic hedgehog pathway has shown in a variety of human cancers, including, basal cell carcinoma, malignant gliomas, medulloblastoma, leukemias, and cancers of the breast, lung, pancreas, and prostate. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 26, 2019 Category: Cancer & Oncology Source Type: news

Chronic TGF-{beta} exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition
Tumors comprise cancer stem cells (CSCs) and their heterogeneous progeny within a stromal microenvironment. In response to transforming growth factor–β (TGF-β), epithelial and carcinoma cells undergo a partial or complete epithelial-mesenchymal transition (EMT), which contributes to cancer progression. This process is seen as reversible because cells revert to an epithelial phenotype upon TGF-β removal. However, we found that prolonged TGF-β exposure, mimicking the state of in vivo carcinomas, promotes stable EMT in mammary epithelial and carcinoma cells, in contrast to the reversible EMT induced ...
Source: Signal Transduction Knowledge Environment - February 26, 2019 Category: Science Authors: Katsuno, Y., Meyer, D. S., Zhang, Z., Shokat, K. M., Akhurst, R. J., Miyazono, K., Derynck, R. Tags: STKE Research Articles Source Type: news

Nonalcoholic fatty liver disease, commonly associated with diabetes, increases the risk of heart disease, and liver, colorectal, and breast cancers
(Natural News) In a new study that was published in the Journal of Hepatology, researchers were able to surmise that nonalcoholic fatty liver disease (NAFLD) is not only associated with hepatocellular carcinoma (HCC), but also to cancers that have nothing to do with the liver, such as colorectal and breast cancers. “NAFLD is a very... (Source: NaturalNews.com)
Source: NaturalNews.com - February 21, 2019 Category: Consumer Health News Source Type: news

Neuromics FBS at 259 USD/500 ml.
Only 2 Weeks LeftWe wanted to get ourFBS in the hands of more cell culturing experts. Our low pricing has accelerated purchasing of this culture supplement.More importantly, we are pleased with the positive feedback. Here are some recentreviews.Linda S.on BirdEye  ★★★★★9 days agoMy experience with Neuromics was very positive. I asked for a sample of FBS and after to use the FBS I received. Peter T.on BirdEye ★★★★★month agoI purchased FBS from Neuromics. It was shipped to Canada without any problems. It arrived safely and still frozen. Cells grow well in the product. Customer ser...
Source: Neuromics - December 15, 2018 Category: Neuroscience Tags: FBS Fetal Bovine Serum Source Type: news

Go Low With Tamoxifen for DCIS Go Low With Tamoxifen for DCIS
In a potentially practice-changing result, use of a 5-mg daily dose of tamoxifen for patients with ductal carcinoma in situ (DCIS) prevented new and recurrent breast cancer events in comparison with placebo.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 7, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Radiation therapy cuts low risk of recurrence by nearly 3/4 for patients with 'good risk'
(American Society for Radiation Oncology) A subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservation surgery but can lower that risk even further with radiation therapy, finds a new long-term clinical trial report. These 12-year follow-up data from the only prospective, randomized trial to compare recurrence outcomes after treatment for low-risk ductal carcinoma in situ (DCIS) were presented last week at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 29, 2018 Category: Cancer & Oncology Source Type: news

Radiation Therapy Cuts Recurrence in'Good Risk' DCIS Radiation Therapy Cuts Recurrence in'Good Risk' DCIS
Whole-breast radiation halved the risk for recurrence in low-risk ductal carcinoma in situ (DCIS), but treatment after surgery needs to part of a physician-patient discussion.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

' Revolutionary' Data to Be Presented at ESMO 2018'Revolutionary' Data to Be Presented at ESMO 2018
Evolutions and even revolutions are expected when the latest data in head and neck cancer, renal cell carcinoma, breast cancer, and ovarian cancer are presented at the leading European cancer meeting.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 11, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Lumpectomy & #43; Radiation May Cut Breast Cancer Mortality in DCIS
MONDAY, Aug. 20, 2018 -- Treatment with lumpectomy and radiotherapy is associated with a reduction in breast cancer mortality versus lumpectomy or mastectomy alone among patients with ductal carcinoma in situ (DCIS), according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 20, 2018 Category: Pharmaceuticals Source Type: news

Lumpectomy Plus RT Tied to Lower Mortality in DCIS Lumpectomy Plus RT Tied to Lower Mortality in DCIS
Lumpectomy plus radiation is associated with a small but statistically significant reduced risk for breast cancer-related death compared to the other major options for ductal carcinoma in situ (DCIS).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 10, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Association of radiation therapy plus lumpectomy in reduced risk of dying in women with DCIS
(JAMA Network) Lumpectomy plus radiation was associated with a small clinical benefit in reduced risk of breast cancer death compared with lumpectomy or mastectomy alone   in women   with ductal carcinoma in situ (DCIS), a noninvasive early form of breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 10, 2018 Category: Cancer & Oncology Source Type: news

Common skin cancer can signal increased risk of other cancers, Stanford researchers say
(Stanford Medicine) People who develop abnormally frequent cases of a skin cancer known as basal cell carcinoma appear to be at significantly increased risk for the development of other cancers, including blood, breast, colon and prostate cancers, according to a preliminary study by researchers at the Stanford University School of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 9, 2018 Category: Cancer & Oncology Source Type: news

Update on Atypical Ductal Hyperplasia Update on Atypical Ductal Hyperplasia
Biomarkers indicating progression to carcinoma are needed for atypical ductal hyperplasia.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 6, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Flight Attendants Have Higher Rates of Many Cancers, Study Says
Flight attendants are exposed to a number of known cancer-causing risks, but few studies have rigorously quantified that risk, and researchers say they are an understudied occupational group. The Harvard Flight Attendant Health Study (FAHS), begun in 2007, addresses some of the gaps in understanding health risks among flight attendants. In the latest report, published in the journal Environmental Health, researchers found that flight attendants had higher rates of many cancers, including breast cancer and melanoma, compared to the general population. The FAHS included more than 5,300 flight attendants who were recruited th...
Source: TIME: Health - June 26, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer healthytime Source Type: news

Women With DCIS Who Are at Low Risk for Recurrence Identified Women With DCIS Who Are at Low Risk for Recurrence Identified
Women with ductal carcinoma in situ (DCIS) who are at low risk for disease recurrence after conservative breast surgery and radiotherapy, and whose treatment could be reduced, have been identified.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Managing Ductal Carcinoma In Situ in the Era of Genomic Profiling
At the 2018 Miami Breast Cancer Conference, Dr. Patrick Borgen presented information related to gene expression profiling as a tool for managing DCIS. (Source: CancerNetwork)
Source: CancerNetwork - March 20, 2018 Category: Cancer & Oncology Authors: Patrick I. Borgen, MD Tags: Breast Cancer Conference Report Conferences/MBCC Source Type: news

Radioactive Seed Localization or Wire-guided Localization of Nonpalpable Invasive and In Situ Breast Cancer: A Randomized, Multicenter, Open-label Trial
This research article has led to a Practice Changing Update in DynaMed Plus. It concludes that radioactive seed localization may have similar positive margin but higher successful placement rates compared to wire localization in women having breast-conserving surgery for nonpalpable invasive breast cancer or ductal carcinoma in situ (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 18, 2018 Category: Consumer Health News Source Type: news

New cancer model shows genomic link between early-stage and invasive breast cancer types
(University of Texas M. D. Anderson Cancer Center) A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ (DCIS) progresses to a more invasive form of cancer say researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 4, 2018 Category: Biology Source Type: news